Investor Presentaiton

Investor presentation ADA 2019 Slide 25 The phase 3a programme STEP and the CV outcomes study SELECT were initiated in 2018 for semaglutide in obesity Semaglutide in obesity phase 3a programme, STEP, expected to include ~4,500 patients¹ Cardiovascular outcomes study, SELECT, initiated for semaglutide in obesity 2018 2019 STEP 1: Weight loss 1,950 patients, 68 weeks STEP 2: T2D non-insulin patients 1,200 patients, 68 weeks STEP 3: Maximising weight loss 600 patients, 68 weeks STEP 4: Maintained weight loss 900 patients, 68 weeks 2020 Expected phase 3a programme completion: 2020 Semaglutide 2.4 mg sc QW ~17,500 people with obesity¹1 Placebo Event-driven Completion: Pre-defined number of events 1 Inclusion criteria: Male or female, age ≥18 years, BMI: ≥30 kg/m² or ≥27 kg/m² and ≥1 comorbidity Note: All treatment arms are adjunct to diet and exercise CV: cardiovascular; T2D: type 2 diabetes; BMI: body mass index 1 Inclusion criteria: Male or female > 45 years, BMI >27 kg/m², myocardial infarction or stroke >60 days, HbA1c <6.5% QW: once-weekly; sc: subcutaneous; BMI: body mass index novo nordisk

View entire presentation